Cite
825-P: Composite Glucose and C-Peptide Endpoints Show Early Efficacy in Recent-Onset Type 1 Diabetes (T1D) Clinical Trials
MLA
Laura M. Jacobsen, et al. “825-P: Composite Glucose and C-Peptide Endpoints Show Early Efficacy in Recent-Onset Type 1 Diabetes (T1D) Clinical Trials.” Diabetes, vol. 71, June 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6da7ce179f162f2f28573677f4087e30&authtype=sso&custid=ns315887.
APA
Laura M. Jacobsen, David D. Cuthbertson, Michael J. Haller, Heba M. Ismail, Emily K. Sims, Stephen E. Gitelman, Diane K. Wherrett, Antoinette Moran, Mark A. Atkinson, Alberto Pugliese, Peter Gottlieb, & Jay Sosenko. (2022). 825-P: Composite Glucose and C-Peptide Endpoints Show Early Efficacy in Recent-Onset Type 1 Diabetes (T1D) Clinical Trials. Diabetes, 71.
Chicago
Laura M. Jacobsen, David D. Cuthbertson, Michael J. Haller, Heba M. Ismail, Emily K. Sims, Stephen E. Gitelman, Diane K. Wherrett, et al. 2022. “825-P: Composite Glucose and C-Peptide Endpoints Show Early Efficacy in Recent-Onset Type 1 Diabetes (T1D) Clinical Trials.” Diabetes 71 (June). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6da7ce179f162f2f28573677f4087e30&authtype=sso&custid=ns315887.